Clinical Scorecard: Geographic Atrophy—Or Is It?
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD) |
| Key Mechanisms | Intravitreal complement inhibitors slow progression of GA |
| Target Population | Patients with advanced stage non-exudative AMD |
| Care Setting | Ophthalmology clinics |
Key Highlights
- Two complement inhibitors approved for GA treatment
- GA is characterized by RPE atrophy visible on OCT
- OCT criteria for cRORA include specific measurements and degeneration evidence
- Differentiation from non-AMD causes is crucial for appropriate treatment
- Multimodal imaging enhances diagnosis and management of GA
Guideline-Based Recommendations
Diagnosis
- Utilize OCT and fundus autofluorescence for accurate identification of GA
- Assess for non-AMD causes of RPE atrophy
Management
- Administer approved complement inhibitors monthly or bi-monthly for GA
Monitoring & Follow-up
- Regular follow-up with imaging to track GA progression
Risks
- Current treatments are not approved for non-AMD conditions
Patient & Prescribing Data
Patients diagnosed with GA secondary to AMD
Complement inhibitors may extend functional vision
Clinical Best Practices
- Employ multimodal imaging for comprehensive assessment
- Ensure accurate diagnosis to avoid inappropriate treatment
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.